GlassScriptPhysician profile
Joelle K Meitl
NPI 1366068173
$1,680.14
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $163 · 2022: $499 · 2023: $861 · 2024: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $279.00 | 2022-2023 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $265.48 | 2021-2024 | Caplyta |
| Abbvie INC. | $247.31 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $137.03 | 2021-2024 | Uzedy, Austedo, Austedo Xr |
| Alkermes, INC. | $134.98 | 2021-2024 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $97.05 | 2022-2023 | Invega Sustenna |
| Lundbeck LLC | $96.88 | 2022-2024 | Brintellix, Rexulti |
| Neurocrine Biosciences, INC. | $79.88 | 2021-2023 | Ingrezza |
| Indivior INC. | $66.85 | 2022-2023 | Perseris |
| Otsuka America Pharmaceutical, INC. | $66.61 | 2023-2024 | Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $66.05 | 2021 | |
| Supernus Pharmaceuticals, INC. | $64.10 | 2023-2024 | Qelbree, Qelbree |
| Biogen, INC. | $19.95 | 2024 | |
| Corium, LLC | $17.26 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.39 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $13.74 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $13.58 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joelle Meitl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.